The UK Department of Health received 51 formal responses from a variety of organizations including the pharmaceutical industry, patient groups, National Health Service bodies and charities, in response to its consultation on changes to the statutory scheme to control the prices of branded medicines.
After considering the responses, the government has decided that option 2a, introducing a payment mechanism applicable to new as well as old products, is the best option.
This requires a payment by companies against sales of new presentations on sale for health service purposes after December 1, 2013, after first deducting discounts and VAT. It is consulting on a payment percentage of between 10% and 17%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze